Eli Lilly is expanding the supply of its weight-loss drug and selling it for half the price of other drugs in the highly lucrative market.  Eli Lilly announced on Tuesday that it is now offering 2.5 mg and 5 mg single-dose vials of tirzepatide, sold under the brand name Zepbound, in response to growing demand. In its last fiscal quarter, the company's earnings surpassed Wall Street expectations due in large part because of the performance of Mounjaro and Zepbound, which have the same active ingredient but h ...

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.Eli Lilly on Tuesday released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to reach millions of patients without insurance coverage for the popular injection, such as those with Medicare. The move also aims to expand the supply of Zepbound in the U.S. as demand skyrockets, and to ensure eligible patients are safely accessing the real treatment as cheaper cop ...

Distributed through LillyDirect®'s self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesityINDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand. The single-dose vials are priced at a 50% or grea ...

Prior to an earnings season, every investor looks for stocks that can beat market expectations. This is because investors always try to position themselves ahead of time and look to tap into stocks that are of high quality.In this regard, we ran a screener that yielded Norwegian Cruise Line Holdings Ltd. (NCLH) , Eli Lilly (LLY) , The Progressive (PGR) and Fortinet (FTNT) as the likely winners on the earnings beat potential.Why is a Positive Earnings Surprise Important?Historically, stocks of companies with ...

Eli Lilly and Company TodayLLYEli Lilly and Company$945.17 -7.57 (-0.79%) 52-Week Range$516.57▼$972.53Dividend Yield0.55%P/E Ratio139.20Price Target$956.88Add to WatchlistEli Lilly and Co. NYSE: LLY is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, known as Mounjaro for type 2 diabetes, and Zepbound for obesity. Its stock is trading back near its all-time high at $972.52. Its market capitalization hovers around the $857 billion mark. The company has many growth ...

The drugmaker looks unstoppable.To paraphrase a Shakespeare quote, bad news and misfortune tend to come in groups. But that may also apply to good news. Just ask Eli Lilly (LLY -0.15%), a pharmaceutical company that has been flying on all cylinders. The drugmaker continues to impress investors with exceptional financial results, impressive regulatory wins, and exciting clinical progress.Much of the company's recent success has to do with tirzepatide, a medicine for diabetes (marketed as Mounjaro) and for ob ...

The S&P 500's top three at year-end could look a little different than they do now.You've likely heard some form of the disclaimer, "Past performance is no guarantee of future results." And the statement is true. However, I'd add something to the disclaimer: "But a big head start is nearly always a good thing."Several large-cap stocks have a big head start that could enable them to finish the year strong. I predict these will be the three best-performing S&P 500 (^GSPC 1.15%) stocks of 2024.1. NvidiaNvidia ...

Eli Lilly's valuation may seem high right now, but with fast earnings growth, today's price could look like a deal in a few years.Eli Lilly (LLY 0.21%) is a growth machine, with its business taking off due to its wildly successful diabetes drug Mounjaro, which recently was approved for weight-loss treatment under the name Zepbound. It could end up being the company's top seller in the near future. There is no shortage of reasons to be bullish on the company.Its sales have been rising at a rapid rate. But as ...

Shares of Eli Lilly (LLY) rose more than 3% on Tuesday after reporting long-term data from the late-stage SURMOUNT-1 study. Data from this study showed that treatment with tirzepatide over three years lowered the risk of developing type 2 diabetes (T2D) by 94% compared with placebo, in obese or overweight adults with pre-diabetes.A dual GIP and GLP-1 receptor agonist, tirzepatide is the active ingredient used in the company’s two blockbuster medications — obesity drug Zepbound and diabetes drug Mounjaro.The ...

Key TakeawaysEli Lilly shares set a record high on Tuesday after announcing that clinical trials of tirzepatide, the medicine used in the company’s diabetes drug Mounjaro and injectable weight loss treatment Zepbound, significantly reduced the risk of developing type 2 diabetes in patients. The stock has oscillated within a broadening wedge since early May last year, with an earnings-driven gap on Aug. 8 accelerating recent bullish momentum.Eli Lilly shares may encounter support around $885 and $790, but ru ...